Will Regulatory Hurdles for Personalized Therapies for Ultra-Rare Genetic Diseases Be Lifted? FDA's Plausible Mechanism Guideline and Five Key Requirements
Background
Ultra-rare genetic diseases, with only a handful of patients worldwide globally, make the design of large-scale randomized controlled trials (RCTs) nearly impossible. Traditional pharmaceutical regulatory frameworks have required patient cohorts numbering in the hundreds to verify statistical significance. This means that even if personalized gene editing technologies or antisense oligonucleotide (ASO) therapeutics are developed, they would remain in an institutional blind spot, unable to enter the formal regulatory approval pathway. In February 2026, the U.S. Food and Drug Administration (FDA) released a draft guidance on Plausible Mechanism targeting a small number of diseases with clearly defined biological pathogenesis mechanisms. This initiative aims to provide flexible review criteria for patient-specific therapies that are difficult to evaluate through conventional clinical trials. However, according to an analysis by Nature Genetics, field researchers and biotech companies must undertake significant preparatory work and infrastructure development to meet these guidelines.
Key Findings
The plausible mechanism framework defined by the guideline centers on five core evaluation criteria. The first requirement is the clear identification of the specific genetic and molecular abnormalities causing the disease; the second is the condition that the therapy must directly target the biological variant identified as the cause of the disease. The third is the acquisition of natural history data, which records the disease progression of untreated patient groups. The fourth step is the confirmation of target engagement, which proves that the drug has reached its target and normalized gene or protein function; the fifth step consists of demonstrating clinical improvement in patients or a significant improvement in validated biomarkers.
Analysts pointed out that the difficulty of achieving these five criteria in the field is not uniform. The first and second criteria can be achieved relatively easily thanks to the maturity of Next-Generation Sequencing (NGS) and oligonucleotide synthesis technologies. On the other hand, the remaining three criteria are identified as difficult barriers to overcome.
In particular, the third requirement, natural history data, is difficult to collect systematically due to the nature of rare diseases with an extremely small number of patients. In diseases affecting fewer than 10 patients worldwide, there is a severe lack of medical history data to serve as a control group, and it is difficult to establish a standard natural history model because the pattern of symptom onset and progression varies for each individual patient. The fourth requirement, confirming target engagement, also faces technical challenges. Since invasive biopsies of central nervous system tissues, such as the brain or spinal cord, are impossible, methods to non-invasively prove that the drug actually acted at the target site are extremely limited. The fifth criterion, demonstrating clinical improvement, also has the limitation that short-term follow-up alone makes it difficult to clearly distinguish mitigation of disease progression.
Implications and Outlook
The FDA's recent guideline is a symbolic milestone signaling that the path to regulatory approval has opened even for personalized medicines for a tiny number of patients. It establishes a regulatory foundation where personalized treatments, which previously remained at the level of compassionate use approval or investigator-initiated trials, can be incorporated into the formal drug approval process. This is expected to provide new development incentives for biotech companies building pipelines for ultra-rare genetic diseases.
However, regulatory flexibility does not guarantee a shortcut to commercialization. Analysts emphasize that companies must build integrated disease registries in collaboration with patient organizations and multinational medical institutions from the early stages of development. Furthermore, it is suggested that research efforts should be concentrated on discovering surrogate biomarkers that can objectively measure the biological activity of drugs. Without an international data-sharing system and public support, the strict standards required by the framework are likely to act as another regulatory barrier for small-scale research teams.
Nature Genetics, Published online: 09 September 2026; doi:10.1038/s41588-026-02750-4In February 2026, the FDA published a draft guidance establishing a plausible mechanism framework for individualized therapies that target rare genetic diseases. The framework is a genuine advance, but its five criteria are not equally tractable, and meeting them will require substantial groundwork for most rare disease programs.
This framework can serve as a specific regulatory guideline for administering single-patient personalized ASOs or gene-editing therapies targeting specific genetic mutations in clinical settings. By preemptively reflecting the five requirements from the research planning stage, hospital Institutional Review Boards (IRBs) and research teams can significantly reduce uncertainty regarding development timelines and review approval processes. From an industrial perspective, a modular new drug development model that shares the same backbone platform while replacing only the target sequence serves as a catalyst for broadening the prospects of regulatory approval. However, since the construction of natural history databases and the validation of non-invasive biomarkers involve significant initial costs, a government-led funding model for rare disease consortia must be organically integrated with industry-academia collaboration platforms to translate into actual patient treatment.